Wang G, Ning FY, Wang JH, Yan HM, Kong HW, Zhang YT, Shen Q. Expression of interleukin-32 in bone marrow of patients with myeloma and its prognostic significance. World J Clin Cases 2019; 7(24): 4234-4244 [PMID: 31911904 DOI: 10.12998/wjcc.v7.i24.4234]
Corresponding Author of This Article
Fang-Ying Ning, MD, Doctor, Department of Hematology, People’s Hospital of Hangzhou Medical College, Zhejiang Provincial People’s Hospital, No. 158 Shangtang Road, Xiacheng District, Hangzhou 310000, Zhejiang Province, China. nfy182110@aliyun.com
Research Domain of This Article
Hematology
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Wang G, Ning FY, Wang JH, Yan HM, Kong HW, Zhang YT, Shen Q. Expression of interleukin-32 in bone marrow of patients with myeloma and its prognostic significance. World J Clin Cases 2019; 7(24): 4234-4244 [PMID: 31911904 DOI: 10.12998/wjcc.v7.i24.4234]
Gang Wang, Jia-Heng Wang, Hong-Wei Kong, Department of Hematology, Quzhou People’s Hospital, Quzhou 324000, Zhejiang Province, China
Fang-Ying Ning, Department of Hematology, People’s Hospital of Hangzhou Medical College, Zhejiang Provincial People’s Hospital, Hangzhou 310000, Zhejiang Province, China
Hai-Meng Yan, Qiang Shen, Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China
Author contributions: Wang G and Ning FY contributed equally to this study; Wang G and Ning FY designed the research; Wang G, Ning FY, Kong HW, Zhang YT and Shen Q performed the research; Yan HM, Kong HW and Zhang YT analyzed the data; Wang G, Ning FY, Wang JH, Yan HM, Kong HW, Zhang YT and Shen Q wrote and revised the paper.
Supported byFoundation for Excellent Young Medical Talents from the Quzhou People's Hospital.
Institutional review board statement: The study was approved by the Ethics Committee of People’s Hospital of Hangzhou Medical College.
Informed consent statement: All patients included in this study gave informed consent.
Conflict-of-interest statement: There is no conflict of interest to declare.
Data sharing statement: No additional data are available.
STROBE statement: The manuscript was prepared and revised according to the STROBE statement.
Corresponding author: Fang-Ying Ning, MD, Doctor, Department of Hematology, People’s Hospital of Hangzhou Medical College, Zhejiang Provincial People’s Hospital, No. 158 Shangtang Road, Xiacheng District, Hangzhou 310000, Zhejiang Province, China. nfy182110@aliyun.com
Received: September 8, 2019 Peer-review started: September 8, 2019 First decision: November 11, 2019 Revised: October 14, 2019 Accepted: November 27, 2019 Article in press: November 27, 2019 Published online: December 26, 2019 Processing time: 108 Days and 6.1 Hours
Core Tip
Core tip: Multiple myeloma (MM) is a heterogeneous disease with a survival time ranging from several months to 20 years, and its clinical manifestations are complex. There are many factors affecting the prognosis. The International Staging System and Durie-Salmon staging have been established to assess prognosis of the disease, but the accuracy of β2-microglobulin and albumin is controversial. In recent years, new prognostic indicators of MM are being continuously investigated. Studies have shown that renal function in association with the degree of bone destruction, and hypercalcemia, can determine the prognosis of MM and predict overall survival (OS). Moreover, minimal residual disease can also predict OS and progression-free survival in patients with MM. We collected data from MM patients in our hospital, analyzed their clinical efficacy, follow-up results and laboratory examination indicators, which suggested that interleukin-32 can be used as an auxiliary indicator for post-treatment efficacy and prognosis assessment.
